NEWS RELEASE
September 26, 2022

Fintepla® (fenfluramine) Approved in Japanfor the Treatment of Seizures Associated with Dravet syndrome

Kyoto, Japan, September 26, 2022 - Nippon Shinyaku Co., Ltd. (Nippon Shinyaku;Headquarters, Kyoto; President, Toru Nakai) announced today that UCB Japan Co. Ltd.
(UCB Japan; Headquarters: Tokyo; President, Kanako Kikuchi) has obtained marketing
approval from the Ministry of Health, Labour and Welfare (MHLW), for Fintepla® Oral Solution
2.2 mg/mL (ZX008; fenfluramine hydrochloride) for the treatment of seizures in patients withDravet syndrome (DS) in Japan.
Fintepla® will be marketed by Nippon Shinyaku based on the exclusive distributionagreement signed in 2019 between Zogenix, Inc. (acquired by UCB S.A. in 2022) and Nippon
Shinyaku, with UCB Japan taking responsibility as the manufacturer and distributor.
DS is a rare, devastating and life-long form of epilepsy that generally begins in infancy or
early childhood and is marked by frequent treatment-resistant seizures, frequent resulting
hospitalizations and medical emergencies, significant developmental and motor andbehavioral impairments. In Japan, DS has been designated as an intractable disease byMHLW, and there are estimated to be about 3,000 patients living with DS in Japan, based on
MHLW Patient Survey.
Fintepla® possesses dual activities to inhibit seizures: acting as a potent 5-HT (serotonin)releaser with agonist activity at several 5-HT receptors, and as a positive modulator of Sigma1 receptor. Fintepla® was designated as an orphan drug by MHLW for the indication of Dravet
syndrome in August, 2021.
Fintepla® is approved in the U.S. and Europe for the treatment of seizures associated withDS in patients two years of age and older. In the U.S., an additional indication of Fintepla®
for the treatment of seizures associated with Lennox-Gastaut syndrome in patients two yearsof age and older was approved in March, 2022.
Nippon Shinyaku is focusing on the field of intractable, rare disorders. We hope that Fintepla®
will contribute to the treatment for patients suffering from DS in Japan.
1/2

【Indications】
The treatment of seizures associated with Dravet syndrome as an add-on therapy to antiepileptic medicines for the patients whose seizures are not controlled by other anti-epileptic
medicines.
【Usage and Dosage】
1. Concomitant use with stiripentol
The usual oral dosage of fenfluramine for adults and children 2 years of age and older is
0.2 mg/kg daily in two divided doses. The dosage may be increased or decreased
according to symptoms to a daily dose not exceeding 0.4 mg/kg, but the dosage should
be increased after an interval of at least one week. The daily dose should not exceed 17mg.
2. Without concomitant use of stiripentol:
The usual oral dosage of fenfluramine for adults and children 2 years of age and older is
0.2 mg/kg daily in two divided doses. The dosage may be increased or decreased
according to symptoms to a daily dose not exceeding 0.7 mg/kg, but the dosage should
be increased after an interval of at least one week. The daily dose should not exceed 26mg.

About Nippon Shinyaku
Our mission is to help people lead healthier and happier lives. Through creating unique
medicines that will bring hope to patients and families struggling with illness, we aim to be anorganization trusted by the community. Please visit our website (https://www.nipponshinyaku.co.jp/english/index.php) for products or detailed information.
About UCB JapanUCB Japan (https://www.ucbjapan.com/) was established in 1988 as the Japanesesubsidiary of UCB S.A., a global biopharmaceutical company headquartered in Brussels,Belgium. The company is developing its pharmaceutical business with a focus on antiepileptic drugs, rheumatoid arthritis and psoriasis drugs. As a biopharmaceutical leader increating value for patients, the company aims to provide new treatment options for patientswho have not achieved satisfactory improvement with conventional therapies.
Contact
Corporate Communications Dept., Nippon Shinyaku
FAX: +81-75-321-9128

2/2